Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs by Meliha Crnkic Kapetanovic et al.
RESEARCH ARTICLE Open Access
Persistence of antibody response 1.5 years after
vaccination using 7-valent pneumococcal
conjugate vaccine in patients with arthritis
treated with different antirheumatic drugs
Meliha Crnkic Kapetanovic1*, Tore Saxne1, Lennart Truedsson2 and Pierre Geborek1
Abstract
Introduction: The aim of this study was to explore the persistence of an antibody response 1.5 years after
vaccination with 7-valent pneumococcal conjugate vaccine in patients with rheumatoid arthritis (RA) or
spondyloarthropathy (SpA) treated with different antirheumatic drugs.
Methods: Of 505 patients initially recruited, data on current antirheumatic treatment and blood samples were
obtained from 398 (79%) subjects after mean (SD, range) 1.4 (0.5; 1 to 2) years. Antibody levels against
pneumococcal serotypes 23F and 6B were analyzed by using enzyme-linked immunosorbent assay (ELISA). Original
treatment groups were as follows: (a) RA receiving methotrexate (MTX); (b) RA taking anti-TNF monotherapy; (c) RA
taking anti-TNF+MTX; (d) SpA with anti-TNF monotherapy; (e) SpA taking anti-TNF+MTX; and (f) SpA taking NSAID/
analgesics. Geometric mean levels (GMLs; 95% CI) and proportion (percentage) of patients with putative protective
antibody levels ≥1 mg/L for both serotypes, calculated in different treatment groups, were compared with results 4
to 6 weeks after vaccination. Patients remaining on initial treatment were included in the analysis. Possible
predictors of persistence of protective antibody response were analysed by using logistic regression analysis.
Results: Of 398 patients participating in the 1.5-year follow up, 302 patients (RA, 163, and SpA, 139) had
unchanged medication. Compared with postvaccination levels at 1.5 years, GMLs for each serotype were
significantly lower in all groups (P between 0.035 and <0.001; paired-sample t test), as were the proportions of
patients with protective antibody levels for both serotypes (P < 0.001; c2 test). Higher prevaccination antibody
levels for both serotypes 23F and 6B were associated with better persistence of protective antibodies (P < 0.001).
Compared with patients with protective antibody levels at 1.5 years, those not having protective antibody levels
were older, more often women, had longer disease duration and higher HAQ and DAS, and had a lower
proportion of initial responders to both serotypes.
Concomitant anti-TNF treatment and MTX were identified as negative predictors of the persistence of protective
antibodies among RA patients (P = 0.024 and P = 0.065, respectively). Only age 65 years or older (P = 0.017) and
not antirheumatic treatment was found to be a negative predictor of protective antibodies in patients with SpA.
Conclusions: After initial increase, 1.5 years after pneumococcal vaccination with 7-valent conjugate vaccine,
postvaccination antibody levels decreased significantly, reaching levels before vaccination in this cohort of patients
with established arthritis treated with different antirheumatic drugs. MTX and anti-TNF treatment predicted low
persistence of protective immunity among patients with RA. To boost antibody response, early revaccination with
conjugate vaccine might be needed in patients receiving potent immunosuppressive remedies.
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Introduction
Infections are a well-recognized cause of increased mor-
bidity and mortality in patients with inflammatory rheu-
matic diseases, partly because of the use of potent
immunomodulating drugs [1-5]. According to recently
published European League Against Rheumatism evi-
dence-based recommendations for vaccination, pneumo-
coccal vaccination should be strongly considered for all
adult patients with rheumatic diseases [6]. Currently
available 23-valent pneumococcal polysaccharide vaccine
covers 85% to 90% of the serotypes causing invasive
pneumococcal disease, such as pneumonia, pneumococ-
cal bacteremia, or meningitis [7]. However, a suboptimal
rate of pneumococcal vaccination among rheumatology
outpatients receiving different immunosuppressive reme-
dies has been reported [8].
Several reasons are found for low pneumococcal vacci-
nation coverage in these patients. One important issue is
the limited evidence of efficacy of the polysaccharide vac-
cine in preventing infections in this high-risk group of
patients, although a recent study reported an increased
risk of developing pneumonia in pneumococcal nonvacci-
nated compared with vaccinated rheumatoid arthritis (RA)
patients receiving methotrexate (MTX) (180 patients fol-
lowed up for 10 years) [9]. Larger controlled studies con-
firming these findings are lacking.
The majority of studies of patients with rheumatic dis-
eases, including those in our earlier reports, investigated
short-term antibody responses after pneumococcal vacci-
nation as surrogate markers of vaccination efficacy [10,11].
Persistence of protective antibodies over time is consid-
ered an indicator of remaining protection against infection
[12-14]. A Finnish study showed initial good antibody
response but returned to close to prevaccination levels
within 3 years after pneumococcal vaccination in an
elderly population [15]. In contrast, Mucher et al. [16]
reported that both primary vaccination and revaccination
induced antibody responses persisting longer than 5 years
in middle-aged and elderly people [16]. Corresponding
studies with immunocompromised patients also report
conflicting results. Systemic lupus erythematosus patients
had a low persistence of protective antibodies at years 1, 2,
and 3 after pneumococcal vaccination compared with
healthy controls [17]. Similarly, antibody levels declined 3
years after vaccination in patients with chronic pulmonary
diseases, HIV-infected individuals, and renal-transplant
recipients [18-20]. Conversely, Coulson et al. [9] found
elevated antibody levels to most pneumococcal polysac-
charides for up to 10 years after vaccination in RA patients
receiving MTX. Reports on the impact of newer antirheu-
matic treatments such as tumor necrosis factor (TNF)
blockers on the persistence of protective antibodies are
lacking. Likewise, the possible advantages of pneumococ-
cal conjugate vaccine on the duration of protective
immunity in adult patients with established arthritis have
not been investigated.
The aim of the present study was to investigate the 1.5-
year persistence of serotype-specific antibodies after conju-
gate pneumococcal vaccination in patients with RA and
spondyloarthropathy (SpA) treated with different antiin-
flammatory remedies, including TNF blockers, compared
with spondyloarthropathy patients treated with NSAID/
analgesics. We also wanted to study the influence of
demographics, disease, and treatment characteristics on
protective antibody levels.
Materials and methods
In total, 505 patients with established arthritis (RA, 253,
and SpA, 252) were initially vaccinated with a single dose
of 0.5 ml of 7-valent pneumococcal conjugate vaccine
intramuscularly, as previously reported [11]. Based on
diagnosis and treatments, patients were divided into six
predefined groups. The groups were as follows: 1. RA on
MTX (n = 85); 2. RA on anti-TNF as monotherapy (n =
79); 3. RA on anti-TNF+MTX (n = 89); 4. SpA on anti-
TNF monotherapy (n = 83); 5. SpA on anti-TNF+MTX
(n = 83), and 6. SpA on NSAID/analgesics (n = 86). Only
patients taking unchanged antirheumatic treatments for at
least 4 weeks before vaccination and 4 to 6 weeks after
vaccination were eligible for the study. Patients were
offered inclusion in a follow-up study that included col-
lecting data on current medication and blood-sample
drawing. Of the original 505 vaccinated patients, 398 parti-
cipated in the 1.5-year follow-up. The mean (SD; range)
time between vaccination and follow-up visit was 1.4 (0.5;
1 to 2) years. Patients who, at the 1.5-year follow-up,
remained on the initial treatment were eligible for the pre-
sent study. Antibody levels against two pneumococcal
polysaccharide antigens (23F and 6B) were measured by
using standardized ELISA, as previously described [21]. All
analyses were performed at the same immunology depart-
ment and by using the same method.
Geometric mean antibody levels (GMLs) for each ser-
otype were calculated and compared with those at vacci-
nation and 4 to 6 weeks after vaccination. Antibody
levels ≥1 mg/L are considered putative protective, and
this level was chosen as protective in the current study
[12,13].
Ethical approval for the vaccination (file number 97/
2007) and additional ethical approval for the follow-up
study (file number 5019/2009) were obtained from the
Ethical Review Board at Lund University. Written
informed consent was obtained from all participants
before inclusion in the study. The study was conducted as
an investigator driven clinical trial, registered on line with
numbers EudraCT 2007-006539-29 and NCT00828997,
and approved by the Swedish medical products agency
(MPA; Läkemedelsverket; file number 151: 2007/88047).
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Statistics
GMLs (95% CI) were calculated from natural logarithm
transformed values of antibody levels. Comparisons
between GMLs were performed using paired samples t
test. A c2 test was used to compare the proportion of
patients with protective antibody levels for each serotype.
In general, the c2 test was used for comparison between
categoric variables and the Mann-Whitney U test for con-
tinuous ones. Possible predictors of protective antibody
levels for all patients included in the study, and RA and
SpA separately, were analyzed by using three different uni-
variate and multivariate logistic regression models.
Results
Of 398 patients participating in the 1.5-year follow-up, 302
patients (RA, 163; and SpA, 139) did not change their anti-
rheumatic treatment during follow-up, and these patients
were included in the analysis.
Number (percentage) and characteristics of patients
remaining on the original antirheumatic treatment at 1.5
years of follow-up are shown in Table 1.
Table 2 summarizes GML (95% CI) in milligrams per
liter and percentage of patients with protective antibody
levels for 23F and 6B in different treatment groups at vac-
cination, at 4 to 6 weeks, and at 1.5-year follow-up. In all
treatment groups, GMLs for each serotype were signifi-
cantly lower at 1.5-year follow-up compared with the
GML 4 to 6 weeks after vaccination (P between 0.035 and
<0.001; paired-sample t test; Figures 1 and 2), as were the
proportions of patients with protective antibody levels for
both serotypes (P < 0.001; c2 test).
GML at 1.5-year follow-up was also lower compared
with prevaccination antibody levels for each serotype in all
treatment groups, but differences were significant only for
RA patients taking anti-TNF+MTX.
SpA patients taking NSAIDs/analgesics (that is, not trea-
ted with immunosuppressive remedies) had significantly
higher proportions of patients with protective antibody
levels both at 4 to 6 weeks and at 1.5 years of follow-up.
Although the proportion of patients with protective anti-
body levels decreased in this group at 1.5-year follow-up,
the relative ratio of protective antibody levels (that is, 1.5-
year follow-up/4 to 6 weeks follow-up) was still highest in
SpA patients with NSAIDs/analgesics. The lowest relative
ratio of protective antibody levels was seen in RA patients
taking anti-TNF+MTX and in general lower in RA
patients than in patients with SpA. The proportions of
patients with protective antibody levels for 23F, 6B, and
both serotypes at vaccination, at 4 to 6 weeks after vacci-
nation, and at 1.5-year follow-up in different treatment
groups are shown in Figure 3.
Clinical and demographic characteristics of patients
after splitting according to protective antibody levels 1.5
years after vaccination (yes/no) are shown in Table 3.
Patients without protective antibodies were on average
older, more frequently women with RA of longer disease
duration, and higher HAQ and DAS at vaccination.
These patients were more often treated with MTX, anti-
TNF, and had concomitant prednisolone treatment. Pro-
tective antibody levels for both serotypes at vaccination,
as well as a positive antibody response for both serotypes
tested, were associated with protective antibody levels at
1.5 years (Table 3).
Predictor analysis
Results of univariate and multivariate regression analysis
for patients with RA and SpA separately are summarized
in Table 4. After adjustments for demographic and disease
characteristics at vaccination, concomitant anti-TNF treat-
ment and treatment with MTX were identified as negative
predictors of persistence of protective antibody levels for
both serotypes tested (P = 0.024 and 0.065, respectively).
Age 65 years or older but not immunosuppressive treat-
ment had a significant negative impact on the persistence
of protective immunity in SpA patients (P = 0.012). Higher
prevaccination antibody levels for both serotypes was a
strong significant predictor of the persistence of protective
antibodies both among RA and SpA patients (P < 0.001).
Table 1 Demographic and disease characteristics of patients receiving the same treatment at vaccination and at 1













Number of patients at vaccination 85 79 89 83 83 86
Number (%) of patients remaining on original
therapy at 1.5-year follow-up
57 (67%) 50 (63%) 56 (63%) 47 (47%) 49 (59%) 43 (50%)
Age, mean (SD); years 63.5 (11) 59.9 (14) 60.5 (9) 50.3 (12) 51.6 (11) 52.8 (12)
Female (%) 77% 90% 75% 38% 57% 49%
Disease duration, mean (SD); years 12.6 (10) 19.8 (11) 16.8 (11) 16.8 (11) 13.1 (10) 13.6 (12)
RF positive (%) 81 86 84 - - -
Anti-CCP positive (%) 77 76 88 - - -
HLA B27 positive (%) - - - 53 33 63
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Analysis of patients who changed their antirheumatic
treatment during follow-up
Altogether, 96 of 398 patients participating in the 1.5-
year follow-up changed their antirheumatic treatment
(RA, 51; and SpA, 45). Mean age and disease duration
(SD) among these RA patients was 59.8 (13.5) and 15.7
(12.7) years, respectively, and 82.4% were women. Of
these 32 patients, 62.7% had protective antibodies for
Table 2 Geometric mean level (GML; 95% CI) in milligrams per liter and percentage of patients with protective
antibody levels for both 23F and 6B in different treatment groups at vaccination, at 4 to 6 weeks, and at 1
RA on
methotrexate













Patient number (n) 85 79 89 83 83 86
GML (95% CI) for 23F 0.7 (0.5-1.1) 0.6 (0.4-0.8) 0.7 (0.5-0.9) 0.7 (0.5-0.9) 0.8 (0.6-1.2) 0.97 (0.7-1.4)
GML (95% CI) for 6B 2.0 (1.4-2.8) 1.4 (0.9-2.0) 1.5 (1.1-2.9) 1.5 (1.1-2.1) 1.7 (1.1-2.5) 2.9 (2.1-4.0)
4 to 6 weeks of follow-up
GML (95% CI) for 23F 1.9 (1.3-2.6) 1.9 (1.3-2.7) 1.4 (1.1-1.9) 3.1 (2.2-4.5) 2.5 (1.8-3.5) 6.4 (4.5-9.1)
GML (95% CI) for 6B 3.5 (2.5-4.9) 3.6 (2.5-5.3) 2.3 (1.7-3.2) 4.8 (3.3-6.9) 3.0 (22.1-4.4) 9.5 (6.7-13.6)
Percentage of patients with protective
antibody levels for both 23F and 6B
67% 58% 52% 78% 65% 84%
1.5-year follow-up
Patient number (n) 57 50 56 47 49 43
GML (95% CI) for 23F 0.6 (0.4-0.8) 0.5 (0.3-0.8) 0.4 (0.3-0.5) 1.0 (0.6-1.6) 0.8 (0.5-1.3) 2.0 (1.3-3.0)
GML (95% CI) for 6B 1.2 (0.7-1.9) 1.0 (0.6-1.7) 0.6 (0.4-1.0) 1.4 (0.9-2.1) 1.0 (0.6-1.6) 2.8 (1.7-4.6)
Percentage of patients with protective
antibody levels for both 23F and 6B
40% 32% 20% 60% 49% 70%
1.5-year follow-up/4 to 6 weeks of follow-up
Relative ratio of protective antibody levels 0.61 0.55 0.38 0.77 0.75 0.84
Figure 1 Antibody levels for serotype 6B at vaccination, at 4 to 6 weeks after vaccination, and at 1.5-year follow-up in patients with
rheumatoid arthritis (RA) and spondyloarthropathy (SpA) treated with different antiinflammatory drugs. Antibody levels ≥1 mg/L were
considered putative protective (short dashed line).
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both serotypes 4 to 6 weeks after vaccination, but only
13 (20.5%) patients had this at 1.5-year follow-up.
Mean age and disease duration (SD) among SpA
patients who had changed their medication at the 1.5-year
follow-up were 51 (12.7) and 13.4 (11.4) years, respectively,
and 46.7% were women. Of these SpA patients, 34 (75.6%)
patients had protective antibody levels for both serotypes
4 to 6 weeks after vaccination, whereas only 18 (40.0%)
patients had this at 1.5-year follow-up.
RA and SpA patients who switched their antirheumatic
treatment had lower proportions of protective antibodies
at 1.5-year follow-up, but no significant differences was
seen in other demographic and disease characteristics
compared with RA and SpA patients remaining on the
original treatment.
Discussion
The main finding in the present report is the low persis-
tence of protective immunity against the serotypes tested
in arthritis patients compared with those reported in
healthy individuals 1 to 2 years after vaccination [16].
Higher age was associated with lower protective antibody
levels in both RA and spondyloarthropathy patients,
regardless of antirheumatic treatment. In general, RA
patients had lower persistence of protective antibodies
compared with SpA patients. The effect of immunosup-
pressive treatments, including both MTX and anti-TNF
drugs on 1.5-year antibody levels, was less clear as
compared with the results 4 to 6 weeks after vaccination,
whereas MTX clearly hampered this response [11].
Our findings of a rapid decline to, and in RA patients
taking anti-TNF and MTX, prevaccination levels already
1.5 years after a single dose of conjugate pneumococcal
vaccine is problematic. However, serum antibody levels
are surrogate markers of vaccine protection, but measur-
ing truly bactericidal antibodies is challenging [12-14]. The
correlation between serum antibody levels and protection
against infections caused by Streptococcus pneumoniae
varies for different populations, serotypes, and infections
[12]. A decline of postvaccination antibody levels probably
results in decreased protection against infections [14]. A
rapid decrease in the antibody levels after pneumococcal
vaccination with 23-valent polysaccharide vaccine has
been reported in subgroups of elderly or immunocompro-
mised individuals [14,15,18-20]. Corroborating results of
conjugate pneumococcal vaccination in immunosup-
pressed patients with inflammatory rheumatic diseases are
lacking, and the effect of repeated vaccination procedures
also needs further studies.
We also found that patients 65 years or older had lower
levels of protective antibodies for both serotypes com-
pared with younger individuals, regardless of treatment.
This could be an effect of age-related decline in immune
responses (immunosenescence), which also includes
impaired ability for B cells to respond to new antigen
challenges [22]. We were unable to detect a statistical
Figure 2 Antibody levels for serotype 23F at vaccination, at 4to 6 weeks after vaccination, and at 1.5-year follow-up in patients with
rheumatoid arthritis (RA) and spondyloarthropathy (SpA) treated with different antiinflammatory drugs. Antibody levels ≥1 mg/L were
considered putative protective (short dashed line).
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interaction between drug treatment and age, suggesting
no specific age-related drug interaction (that is, an
increased sensitivity to drug-induced immunosuppres-
sion) did not seem to occur in old individuals, other than
immunosenescence. However, a possible impact of RA
disease itself on vaccine response cannot be ruled out.
Both MTX and anti-TNF treatment were negative pre-
dictors of the persistence of protective immunity at 1.5
years when analyzed among all patients (Table 4). When
we analyzed RA patients separately, concomitant anti-
TNF treatment remained a negative predictor, whereas
MTX showed only a trend in RA. In SpA patients 65 years
or older, a negative effect on persistence of protective anti-
bodies appeared, but treatment did not affect antibody
persistence significantly. Overall, more SpA patients had
protective antibodies levels for each serotype compared
with the corresponding RA treatment groups. Expectedly,
SpA patients taking NSAIDs/analgesics without concomi-
tant immunosuppressive drugs had the highest persistence
of protective antibodies, although not statistically different
from SpA on anti-TNF monotherapy. Patients with SpA
participating in the present study were younger; a larger
proportion were men; they had longer disease duration,
and one third were not treated with immunosuppressive
remedies, which all may have contributed to these diver-
ging results. Because RA diagnosis itself was associated
with a lower persistence of protective antibodies, the dif-
ference in immunologic disturbance as a part of each dis-
ease may play a role.
Furthermore, we previously reported that prednisolone
improved antibody response 4 to 6 weeks after pneumo-
coccal vaccination in this cohort [11]. However, neither
use of prednisolone nor dosage of prednisolone had any
significant impact on the persistence of protective antibo-
dies after 1.5 years. These results are consistent with pre-
viously reported data on the influence of systemic steroids
on immunogenicity of pneumococcal polysaccharide vac-
cine in patients with chronic obstructive lung disease 12
month after the vaccination [23].
Results from the present study are in line with some
previously published data, including those from other
immunocompromised patients, such as HIV-infected
patients or renal transplant recipients, in whom antibody
response after pneumococcal vaccination with either
polysaccharide or conjugate vaccine was shown to
decline significantly by 3 years [19,20]. In contrast, sus-
tained antibody levels up to 10 years after pneumococcal
vaccination in 124 consecutive RA patients taking MTX
have recently been reported [9]. Patients participating in
that study received the vaccine early in the course of RA
and were significantly younger at vaccination. All partici-
pants were taking MTX at vaccination and had a stable
MTX dose for at least a year before enrolment in the
study, occurring approximately 10 years after vaccination.
Furthermore, it seems that none of the patients in that
study had received concomitant DMARDs or biologics.
This indicates that the study population represents a
selection of younger patients with early RA sufficiently
treated with MTX and with good compliance with the
treatment, making the results less comparable with those
in our report.
Regardless of treatment and diagnosis, we found that
high prevaccination antibody levels predicted a better per-
sistence of protective immunity at the 1.5-year follow-up.
This is consistent with a previously reported association
between high prevaccination antibody levels and better
vaccination response [24]. The high prevaccination anti-
body levels are most likely due to natural pneumococci
exposure or cross-reacting bacteria in vaccine-naive
patients.
Patients participating in this study received a dose of
7-valent conjugate polysaccharide vaccine. Through con-
jugation of pneumococcal polysaccharide antigen to a
Figure 3 Percentage of patients with putative protective
antibody levels (≥1 mg/L) for serotype 23 F 6B and both 23 F
and 6 B (C) at vaccination, at 4 to 6 weeks after vaccination,
and at 1.5-year follow-up in patients with rheumatoid arthritis
(RA) and spondyloarthropathy (SpA) treated with different
antiinflammatory drugs.
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polypeptide carrier protein, this vaccine stimulates B-cell
production of antibodies and their development into
memory cells. However, we could not see that this
pneumococcal conjugate vaccine has any advantage over
23-polysaccharide vaccine, either on antibody produc-
tion of serotype-specific antibodies or on the persistence
of protective antibodies in immunosuppressed patients
with arthritis. Conversely, we did not test whether
revaccination would have any effect on memory cells
[25].
The group of patients that changed the antirheumatic
treatment during the follow-up period was relatively
small and could not be analyzed in detail. However,
overall, the frequency of protective antibodies was quite
Table 3 Disease and demographic characteristics of patients based on the status of protective antibody levels at 1
Patients with protective antibody
levels at 1.5 years of follow-up
(n = 132)
Patients without protective antibody
levels at 1.5 years of follow-up
(n = 170)
P value
Age (years); mean (SD) (range) 51.7 (13) (24-79) 60.1 (11) (30-85) P < 0.001a
Patient age ≥65 years (%) 16% 37% P < 0.001b
Gender (female %) 58% 72% P = 0.01b
Disease duration (years); mean (SD) (range) 13.8 (10) (0-45) 16.7 (11) (0-46) P = 0.039a
DAS at vaccination; mean (SD) (range) 3.0 (1.3) (0-5.6) 3.5 (1) (0-6.4) P = 0.001a
HAQ at vaccination; mean (SD) (range) 0.6 (0.5) (0-2) 0.9 (0.7) (0-3) P < 0.001a
RA (yes, %) 38/62 66/34 P < 0.001b
Ongoing MTX (yes, %) 44% 61% P < 0.001b
Ongoing anti-TNF treatment (yes, %) 60% 72% P = 0.029b
Positive antibody response for 6B and 23F at
4 to 6 weeks of follow-up (yes, %)
37.1% 25% P = 0.027b
Protective antibody levels for both 6B and
23F serotypes at vaccination (%)
72% 20.6% P < 0.001b
aMann-Whitney U test. bc2 test.
Table 4 Predictors of persistence of protective antibody levels for both 23F and 6B 1.5 years after pneumococcal
vaccination by using 7-valent conjugate vaccine in patients with rheumatoid arthritis and spondyloarthropathy
Univariate logistic regression analysis
RA
P value; OR (95% CI)
Spondyloarthropathy
P value; OR, 95% CI
Age ≥65 years (yes/no) P = 0.144; OR 0.59 (0.29-1.2) P = 0.012; OR 0.24 (0.08-0.74)
Gender (male/female) P = 0.727; OR 0.86 (0.37-2.0) P = 0.120; OR 1.72 (0.07-3.40)
Disease duration (years) P = 0.011; OR 0.96 (0.93-0.99) P = 0.895; OR 1.0 (0.97-1.03)
DAS at vaccination (0-6.5) P = 0.684; OR 0.94 (0.68-1.28) P = 0.014; OR 0.70 (0.51-0.93)
HAQ at vaccination (0-3) P = 0.020; OR 0.54 (0.32-0.91) P = 0.043; OR 0.48 (0.24-0.98)
Ongoing MTX (yes/no) P = 0.807; OR 0.92 (0.45-1.9) P = 0.078; OR 0.53 (0.26-1.07)
Ongoing anti-TNF (yes/no) P = 0.066; OR 0.53 (0.27-1.04) P = 0.086; OR 0.51 (0.24-1.1)
Ongoing prednisolone (yes/no) P = 0.259; OR 0.64 (0.29-1.40) P = 0.390; OR 0.62 (0.21-1.84)
Positive antibody response for both 6B and 23F at 4 to 6 weeks P = 0.180; OR 1.70 (0.78-3.71) P = 0.630; OR 1.19 (0.59-2.36)
Protective prevaccination antibody levels for both 23F and 6B (yes/no) P < 0.001; OR 12.1 (5.38-27.4) P < 001; OR 14.6 (5.83-36.4)
Multivariate logistic regression analysis
Age ≥65 years (yes/no) P = 0.188; OR 0.59 (0.26-1.30) P = 0.017; OR 0.22 (0.06-0.76)
Gender (male/female) P = 0.480; OR 0.70 (0.26-1.88) P = 0.637; OR 1.24 (0.51-2.97)
Disease duration (years) P = 0.214; OR 0.98 (0.94-1.01) P = 0.873; OR 1.01 (0.97-1.04)
HAQ at vaccination (0-3) P = 0.139; OR 0.62 (0.32-1.17) P = 0.291; OR 0.63 (0.27-1.49)
Ongoing MTX (yes/no) P = 0.065; OR 0.39 (0.14-1.06) P = 0.882; OR 0.94 (0.39-2.27)
Ongoing anti-TNF (yes/no) P = 0.024; OR 0.34 (0.13-0.87) P = 0.195; OR 0.54 (0.21-1.37)
Positive antibody response for both 6B and 23F at 4-6 weeks P = 0.388; OR 1.45 (0.62-3.40) P = 0.916; OR 1.04 (0.49-2.23)
Adjusted for age older than 65 years, gender, disease duration, HAQ, ongoing MTX, ongoing anti-TNF, and positive antibody response for both serotypes tested.
MTX, methotrexate; HAQ, health-assessment questionnaire.
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low at 1.5-year follow-up in both RA and SpA patients,
suggesting that this group did benefit to a lesser degree
from the vaccination.
In the immunology laboratory where the analysis of anti-
body levels was performed, antibody levels ≥1 mg/L are
considered protective. These antibody levels were shown
to correlate with age-dependent efficacy of polysaccharide
vaccines [13]. However, the relation between antibody
levels and protection against pneumococcal disease is a
controversial issue [12]. Because no general recommenda-
tions for protective antibody levels in adults are available,
the clinical significance of the declines in detectable anti-
bodies is not clear. This remains a limitation of the present
study. Nevertheless, antibody levels decreasing to those
before vaccination suggest lack of protection already after
1.5 years.
Revaccination against invasive pneumococcal diseases by
using 23-valent pneumococcal polysaccharide vaccine is
recommended as early as 5 years after primary vaccination
[6,7]. Our data indicate that revaccination earlier than
recommended may be needed in patients with established
arthritis.
Conclusions
The persistence of protective immunity was low at 1.5
years after vaccination with pneumococcal conjugate vac-
cine in patients with established arthritis treated with dif-
ferent antirheumatic drugs. To boost antibody response,
early revaccination with conjugate vaccine might be
needed in arthritis patients receiving potent immunosup-
pressive remedies.
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